Tony Berberabe on Muck Rack

Tony Berberabe

Verified
Cranbury
As seen in: Targeted Oncology, NewsBreak, American Journal of Managed Care, ONCOLOGY journal, CURE Magazine, OncLive, Our Community Now, Urology Times, Oncology Nursing News, CGTLive
Assistant Managing Editor, Targeted Therapies in Oncology. Tweets are my own.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Tony

Contact Tony, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

FDA Approves Teclistamab Combination for R/R Multiple Myeloma in Latest CNPV Review

|
By Bridget Hoyt, Antonio Ocejo, Tony Berberabe 
| Oncology Nursing News
The FDA has approved teclistamab (Tecvayli) daratumumab and hyaluronidase-fihj (Darzalex Faspro) for the treatment of patients with relapsed or refractory multiple myeloma following at least 1 line of prior therapy including a proteasome inhibitor and an immunomodulatory agent.1 With this approval, the accelerated approval of teclistamab monotherapy in adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior lines of therapy including a proteasome...
Open in Who Shared View Duplicates (6) Issue with article?

First-Line Abiraterone Combo Doubles PFS in Biomarker-Selected mCRPC

|
By Tony Berberabe , Jonah Feldman, Ryan Scott 
| Oncology Nursing News
Among patients with metastatic castration-resistant prostate cancer (mCRPC) harboring BRCA1/2 or ATM alterations, the combination of abiraterone acetate (Zytiga)/prednisone and olaparib (Lynparza) was well tolerated and yielded superior survival and response rates vs either agent alone or used sequentially, according to phase 2 BRCAAway trial (NCT03012321) findings presented at the 2026 ASCO Genitourinary Cancers Symposium in San Francisco, California.
Open in Who Shared Issue with article?

Belzutifan Plus Lenvatinib Favored Vs Cabozantinib in ccRCC

|
By Claire C. Conley, Marcelo M. Sleiman, Tony Berberabe 
| Oncology Nursing News
Belzutifan (Welireg), a HIF-2α inhibitor, combined with lenvatinib (Lenvima) yielded superior progression-free survival (PFS) and objective response rate (ORR) compared with cabozantinib (Cabometyx) in patients with advanced clear cell renal cell carcinoma (ccRCC) after immune checkpoint inhibitor therapy, according to results from the LITESPARK-011 trial (NCT04586231) presented by Robert J. Motzer, MD, at the 2026 ASCO Genitourinary Cancers Symposium.
Open in Who Shared Issue with article?
See all 121 licensed articles (896 Total)

Actions

Share this page

Get in touch with Tony

Contact Tony, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified